Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
Subscribe To Our Newsletter & Stay Updated
